摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-氟-3-羟甲基-4-碘吡啶 | 171366-19-1

中文名称
2-氟-3-羟甲基-4-碘吡啶
中文别名
2-氟-4-碘吡啶-3-甲醇;2-氟-4-碘-3-吡啶甲醇
英文名称
2-Fluoro-4-iodo-3-(hydroxymethyl)pyridine
英文别名
(2-fluoro-4-iodo-pyridin-3-yl)-methanol;(2-fluoro-4-iodopyridin-3-yl)methanol
2-氟-3-羟甲基-4-碘吡啶化学式
CAS
171366-19-1
化学式
C6H5FINO
mdl
MFCD03095295
分子量
253.015
InChiKey
FQCZQIGAGKWNEA-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    330.4±37.0 °C(Predicted)
  • 密度:
    2.061

计算性质

  • 辛醇/水分配系数(LogP):
    1.1
  • 重原子数:
    10
  • 可旋转键数:
    1
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.166
  • 拓扑面积:
    33.1
  • 氢给体数:
    1
  • 氢受体数:
    3

安全信息

  • 危险性防范说明:
    P261,P305+P351+P338
  • 危险性描述:
    H315,H319,H335
  • 储存条件:
    存储条件:2-8℃,避光,惰性气体保护。

SDS

SDS:22385affde1cb678674cc034030bfdf3
查看

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

点击查看最新优质反应信息

文献信息

  • Method of making asymmetric DE ring intermediates for the synthesis of
    申请人:North Carolina State University
    公开号:US05496952A1
    公开(公告)日:1996-03-05
    The present invention is directed towards new methods of making DE ring intermediates of Formula (III), ##STR1## wherein Y is H or halogen and R is loweralkyl, which in turn are useful in methods of making camptothecin and camptothecin analogs. The present invention also provides new compounds useful in the methods of making compounds of Formula (III).
    本发明涉及制备DE环中间体的新方法,该中间体的化学式为(III),其中Y为H或卤素,R为低碳基。该中间体在制备喜树碱和喜树碱类似物的方法中有用。本发明还提供了在制备化合物(III)的方法中有用的新化合物。
  • New camptothecin analogue compounds
    申请人:——
    公开号:US20020077325A1
    公开(公告)日:2002-06-20
    Compound of formula (I): 1 wherein: n is 0, 1 or 2, R 1 , R 2 , R 3 , R 4 and R 5 are selected from hydrogen, halogen, alkyl, alkenyl, alkynyl, perhaloalkyl, cycloalkyl, cycloalkylalkyl, hydroxy, hydroxyalkyl, alkoxy, alkoxyalkyl, alkoxycarbonyl, acyloxy, carboxy, nitro, cyano, aminocarbonyl (optionally substituted), and the groups (CH 2 ) p —NR a R b and —O—C(O)—N—R a R b , with p, R a and R b being as defined in the description, or two adjacent groups R 2 , R 3 , R 4 and R 5 together form a group —O—(CH 2 ) t —O, t being an integer from 1 to 3), R 60 , R 70n , R 80 and R 90 represent a hydrogen atom, a hydroxy group, an alkoxy group, or an O—(CO)—X or O—(CO)—NXW group as defined in the description, R 61 , R 71n , R 81 and R 91 represent a hydrogen atom , alkyl, alkenyl or alkynyl, or taken in pairs together form a bond or an oxirane group, or two groups together form an oxo group. and medicinal products containing the same are useful for the treatment of cancerous diseases.
    化合物的式子(I):其中:n为0、1或2,R1、R2、R3、R4和R5选择自氢、卤素、烷基、烯基、炔基、全氟烷基、环烷基、环烷基烷基、羟基、羟基烷基、烷氧基、烷氧基烷基、烷氧羰基、酰氧基、羧基、硝基、氰基、氨基羰基(可选择性取代),以及(CH2)p-NRaRb和-O-C(O)-N-RaRb这些基团,其中p、Ra和Rb如描述中所定义,或者相邻的两个基团R2、R3、R4和R5共同形成一个-O-(CH2)t-O的基团,其中t为1到3的整数。R60、R70n、R80和R90代表氢原子、羟基、烷氧基或描述中定义的O-(CO)-X或O-(CO)-NXW基团。R61、R71n、R81和R91代表氢原子、烷基、烯基或炔基,或者成对地共同形成键或环氧丙烷基团,或者两个基团共同形成一个羰基团。含有这些化合物的药品对于治疗癌症疾病是有用的。
  • New campothecin analogue compounds
    申请人:——
    公开号:US20030105109A1
    公开(公告)日:2003-06-05
    Compound of formula (I): 1 wherein: n is 0, 1 or 2, R 1 represents (C 3 -C 11 )cycloalkyl or (C 3 -C 11 )cycloalkylalkyl, R 2 , R 3 , R 4 and R 5 are selected from hydrogen, halogen, alkyl, alkenyl, alkynyl, perhaloalkyl, cycloalkyl, cycloalkylalkyl, hydroxy, hydroxyalkyl, alkoxy, alkoxyalkyl, alkoxycarbonyl, acyloxy, carboxy, nitro, cyano, aminocarbonyl (optionally substituted), and the groups (CH 2 ) p —N a R b and —O—C(O)—N—R a R b , with p, R a and R b being as defined in the description, or two adjacent groups R 2 , R 3 , R 4 and R 5 together form a group —O—(CH 2 ) t —O, t being an integer from 1 to 3, R 60 , R 70n , R 80 and R 90 represent a hydrogen atom, a hydroxy group, an alkoxy group, or an O—(CO)—X or O—(CO)—NXW group as defined in the description, R 61 , R 71n , R 81 , and R 91 represent a hydrogen atom, alkyl, alkenyl or alkynyl, or taken in pairs together form a bond or an oxirane group, or two groups together form an oxo group. and medicinal products containing the same are useful for the treatment of cancerous disesases.
    式(I)的化合物: 其中: n为0、1或2, R1代表(C3-C11)环烷基或(C3-C11)环烷基烷基, R2、R3、R4和R5选择自氢、卤素、烷基、烯基、炔基、全卤烷基、环烷基、环烷基烷基、羟基、羟基烷基、烷氧基、烷氧基烷基、烷氧羰基、酰氧基、羧基、硝基、氰基、氨基羰基(可选地取代)和(CH2)p—NaRb和—O—C(O)—N—RaRb基团,其中p、Ra和Rb如描述中定义,或者相邻的两个基团R2、R3、R4和R5组成—O—(CH2)t—O基团,其中t为1到3的整数, R60、R70n、R80和R90代表氢原子、羟基、烷氧基,或者如描述中所定义的O—(CO)—X或O—(CO)—NXW基团, R61、R71n、R81和R91代表氢原子、烷基、烯基或炔基,或成对地共同形成键或环氧基团,或两个基团共同形成氧基团。 含有该化合物的药物对治疗癌症有用。
  • Camptothecin analogue compounds
    申请人:Les Laboratoires Servier
    公开号:US06509345B2
    公开(公告)日:2003-01-21
    Compound of formula (I): wherein: n is 0, 1 or 2, R1, R2, R3, R4 and R5 are selected from hydrogen, halogen, alkyl, alkenyl, alkynyl, perhaloalkyl, cycloalkyl, cycloalkylalkyl, hydroxy, hydroxyalkyl, alkoxy, alkoxyalkyl, alkoxycarbonyl, acyloxy, carboxy, nitro, cyano, aminocarbonyl (optionally substituted), and the groups (CH2)p—NRaRb and —O—C(O)—N—RaRb, with p, Ra and Rb being as defined in the description, or two adjacent groups R2, R3, R4 and R5 together form a group —O—(CH2)t—O, t being an integer from 1 to 3, R60, R70n, R80 and R90 represent a hydrogen atom, a hydroxy group, an alkoxy group, or an O—(CO)—X or O—(CO)—NXW group as defined in the description, R61, R71n, R81 and R91 represent a hydrogen atom, alkyl, alkenyl or alkynyl, or taken in pairs together form a bond or an oxirane group, or two groups together form an oxo group. and medicinal products containing the same are useful for the treatment of cancerous diseases.
    化合物的公式(I):其中:n为0、1或2,R1、R2、R3、R4和R5从氢、卤素、烷基、烯基、炔基、全卤烷基、环烷基、环烷基烷基、羟基、羟基烷基、烷氧基、烷氧基烷基、烷氧羰基、酰氧基、羧基、硝基、氰基、氨基羰基(可选择性取代)和(CH2)p-NRaRb和-O-C(O)-N-RaRb这些基团中选择,其中p、Ra和Rb在说明中定义,或者相邻的两个基团R2、R3、R4和R5结合形成一个-O-(CH2)t-O基团,其中t为1到3的整数,R60、R70n、R80和R90代表氢原子、羟基、烷氧基或根据说明中定义的O-(CO)-X或O-(CO)-NXW基团,R61、R71n、R81和R91代表氢原子、烷基、烯基或炔基,或者成对地结合形成键或环氧基团,或者两个基团结合形成一个酮基团。含有这些化合物的药物对于治疗癌症疾病是有用的。
  • BROMODOMAIN INHIBITORS AND USES THEREOF
    申请人:Albrecht Brian K.
    公开号:US20120157428A1
    公开(公告)日:2012-06-21
    The present invention relates to compounds useful as inhibitors of bromodomain-containing proteins. The invention also provides pharmaceutically acceptable compositions comprising compounds of the present invention and methods of using said compositions in the treatment of various disorders.
    本发明涉及用作抑制含有溴结构域的蛋白质的化合物。本发明还提供了包括本发明化合物的药学上可接受的组合物,以及使用该组合物治疗各种疾病的方法。
查看更多

同类化合物

(S)-氨氯地平-d4 (R,S)-可替宁N-氧化物-甲基-d3 (R)-N'-亚硝基尼古丁 (5E)-5-[(2,5-二甲基-1-吡啶-3-基-吡咯-3-基)亚甲基]-2-亚磺酰基-1,3-噻唑烷-4-酮 (5-溴-3-吡啶基)[4-(1-吡咯烷基)-1-哌啶基]甲酮 (5-氨基-6-氰基-7-甲基[1,2]噻唑并[4,5-b]吡啶-3-甲酰胺) (2S)-2-[[[9-丙-2-基-6-[(4-吡啶-2-基苯基)甲基氨基]嘌呤-2-基]氨基]丁-1-醇 (2R,2''R)-(+)-[N,N''-双(2-吡啶基甲基)]-2,2''-联吡咯烷四盐酸盐 黄色素-37 麦斯明-D4 麦司明 麝香吡啶 鲁非罗尼 鲁卡他胺 高氯酸N-甲基甲基吡啶正离子 高氯酸,吡啶 高奎宁酸 马来酸溴苯那敏 马来酸左氨氯地平 顺式-双(异硫氰基)(2,2'-联吡啶基-4,4'-二羧基)(4,4'-二-壬基-2'-联吡啶基)钌(II) 顺式-二氯二(4-氯吡啶)铂 顺式-二(2,2'-联吡啶)二氯铬氯化物 顺式-1-(4-甲氧基苄基)-3-羟基-5-(3-吡啶)-2-吡咯烷酮 顺-双(2,2-二吡啶)二氯化钌(II) 水合物 顺-双(2,2'-二吡啶基)二氯化钌(II)二水合物 顺-二氯二(吡啶)铂(II) 顺-二(2,2'-联吡啶)二氯化钌(II)二水合物 非那吡啶 非洛地平杂质C 非洛地平 非戈替尼 非尼拉朵 非尼拉敏 阿雷地平 阿瑞洛莫 阿培利司N-6 阿伐曲波帕杂质40 间硝苯地平 间-硝苯地平 锇二(2,2'-联吡啶)氯化物 链黑霉素 链黑菌素 银杏酮盐酸盐 铬二烟酸盐 铝三烟酸盐 铜-缩氨基硫脲络合物 铜(2+)乙酸酯吡啶(1:2:1) 铁5-甲氧基-6-甲基-1-氧代-2-吡啶酮 钾4-氨基-3,6-二氯-2-吡啶羧酸酯 钯,二氯双(3-氯吡啶-κN)-,(SP-4-1)-